Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.

In cases in which the TNBC‐RPS was not statistically significant compared to other signatures, a positive trend in the T‐score was observed; this still indicates a better prediction ability when using the TNBC‐RPS as the predictor. 3.4 The TNBC‐RPS predicts NCT response in each clinical stage and grade Although the TNBC‐RPS showed good prediction power in TNBC patients, we were concerned that tumor stage or grade might have confounded these findings; it has been reported that TNBC patients with a more advanced tumor stage or grade tend to have better response to NCT. 59 To evaluate this, we first examined the predictive ability of the TNBC‐RPS in the validation metadata for each tumor stage.

also in 11,005 other papers